SG11201408697QA - Methods and compositions for natural killer cells - Google Patents

Methods and compositions for natural killer cells

Info

Publication number
SG11201408697QA
SG11201408697QA SG11201408697QA SG11201408697QA SG11201408697QA SG 11201408697Q A SG11201408697Q A SG 11201408697QA SG 11201408697Q A SG11201408697Q A SG 11201408697QA SG 11201408697Q A SG11201408697Q A SG 11201408697QA SG 11201408697Q A SG11201408697Q A SG 11201408697QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
natural killer
killer cells
cells
Prior art date
Application number
SG11201408697QA
Other languages
English (en)
Inventor
Alicja Copik
Vijay Reddy
Jeremiah Oyer
Original Assignee
Univ Central Florida Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found filed Critical Univ Central Florida Res Found
Publication of SG11201408697QA publication Critical patent/SG11201408697QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11201408697QA 2012-06-28 2013-06-28 Methods and compositions for natural killer cells SG11201408697QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665591P 2012-06-28 2012-06-28
PCT/US2013/048678 WO2014005072A1 (en) 2012-06-28 2013-06-28 Methods and compositions for natural killer cells

Publications (1)

Publication Number Publication Date
SG11201408697QA true SG11201408697QA (en) 2015-02-27

Family

ID=49783918

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408697QA SG11201408697QA (en) 2012-06-28 2013-06-28 Methods and compositions for natural killer cells
SG10201610915XA SG10201610915XA (en) 2012-06-28 2013-06-28 Methods and compositions for natural killer cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201610915XA SG10201610915XA (en) 2012-06-28 2013-06-28 Methods and compositions for natural killer cells

Country Status (16)

Country Link
US (5) US9623082B2 (hu)
EP (3) EP3578201B1 (hu)
AU (3) AU2013282353B2 (hu)
CA (1) CA2877968A1 (hu)
DK (1) DK3578201T3 (hu)
ES (1) ES2943932T3 (hu)
FI (1) FI3578201T3 (hu)
HR (1) HRP20230424T1 (hu)
HU (1) HUE061931T2 (hu)
LT (1) LT3578201T (hu)
PL (1) PL3578201T3 (hu)
PT (1) PT3578201T (hu)
RS (1) RS64172B1 (hu)
SG (2) SG11201408697QA (hu)
SI (1) SI3578201T1 (hu)
WO (1) WO2014005072A1 (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP2824112B1 (en) * 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
WO2016069607A1 (en) * 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR102650803B1 (ko) * 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore ABBREVIATED NKG2D CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2018218151A1 (en) * 2017-05-25 2018-11-29 University Of Central Florida Research Foundation, Inc. Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
WO2019165097A1 (en) * 2018-02-21 2019-08-29 Board Of Regents,The University Of Taxas System Universal antigen presenting cells and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN109627342B (zh) * 2018-12-10 2022-12-06 苏州近岸蛋白质科技股份有限公司 应用于nk细胞培养的蛋白质、培养基配方组合及制备方法
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
CA3127459A1 (en) * 2019-01-24 2020-07-30 University Of Central Florida Research Foundation, Inc. Compositions and methods for stimulating natural killer cells
WO2020160047A2 (en) * 2019-01-28 2020-08-06 Rhode Island Council On Postsecondary Education Phlip® peptide-mediated epitope tethering at cell surfaces
US12029793B2 (en) * 2019-01-28 2024-07-09 Yale University pH low insertion peptide targeted delivery of potent cytotoxic compounds
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3935159A1 (en) 2019-03-08 2022-01-12 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20220259284A1 (en) 2019-06-12 2022-08-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020301417A1 (en) * 2019-06-25 2022-01-06 City Of Hope PDL1 positive NK cell cancer treatment
CN112391349B (zh) * 2019-08-19 2023-05-23 刘韬 滋养层细胞株及其制备方法和体外诱导扩增nk细胞的方法
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
CN113646435A (zh) * 2019-12-09 2021-11-12 南克维斯特公司 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆
KR20220139319A (ko) 2020-01-08 2022-10-14 옵시디안 테라퓨틱스, 인크. 조정 가능한 전사의 조절을 위한 조성물 및 방법
WO2021188974A1 (en) * 2020-03-20 2021-09-23 Orgenesis Inc. Ribonucleases for treating viral infections
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
CN115461451A (zh) * 2020-06-09 2022-12-09 社会福祉法人三星生命公益财团 用于激活和增幅nk细胞的经基因改造的细胞株以及其用途
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof
US20240299542A1 (en) 2021-01-05 2024-09-12 City Of Hope Natural killer cells engineered to reduce or eliminate cbl-b and uses thereof
KR20240036997A (ko) * 2022-09-14 2024-03-21 재단법인 한국마이크로의료로봇연구원 사이토카인 활성 강화된 자연살해세포 유래 엑소좀의 암 치료용 생물학적 조성물 및 이의 용도
CN117987365B (zh) * 2023-12-27 2024-08-06 常州市第一人民医院 一种裂亡前列腺癌细胞囊泡的工程化改造方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849452B1 (en) * 1998-03-03 2005-02-01 Institut Gustave Roussy Methods for activating natural killer (NK) cells and means for carrying out said methods
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP1178785B1 (en) * 1999-05-06 2008-12-24 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
DE60138222D1 (de) * 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
CA2446739A1 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030148454A1 (en) * 2001-11-02 2003-08-07 Trustees Of Boston University Virus-free vesicles for delivery of functional membrane bound proteins
WO2004098529A2 (en) * 2003-04-30 2004-11-18 Emory University Therapeutic compositions and vaccines by glycosyl-phosphatidylinositol (gpi)-anchored cytokines and immunostimulatory molecules
AU2004266034B2 (en) * 2003-08-21 2011-01-27 Lipotek Pty Ltd In vivo targeting of dendritic cells
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20060073591A1 (en) 2004-01-09 2006-04-06 Abitorabi M A Cell culture media
WO2005124346A1 (en) * 2004-05-17 2005-12-29 The Board Of Trustees Of The University Of Illinois 4-1bb receptors are expressed on regulatory t-cells
CA2589034C (en) 2004-11-02 2016-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
CA2504279A1 (en) * 2005-04-15 2006-10-15 University Of Saskatchewan Materials and method of modulating the immune response using t helper-antigen presenting cells
PT1963369E (pt) * 2005-11-28 2013-05-28 Zymogenetics Inc Antagonistas de il-21
KR20080090412A (ko) * 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 생체내 세포 표면 엔지니어링
JP5591712B2 (ja) * 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー／エス ヒトｎｋｇ２ｄに対する抗体とその使用
WO2010071836A1 (en) * 2008-12-19 2010-06-24 Inserm Il-15 mediated nk and t cell maturation
AR083044A1 (es) * 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
US20140234320A1 (en) * 2011-06-20 2014-08-21 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013175237A1 (en) 2012-05-24 2013-11-28 Ucl Business Plc Composition comprising a cd2 ligation agent and a nkg2d ligation agent

Also Published As

Publication number Publication date
US9623082B2 (en) 2017-04-18
HRP20230424T1 (hr) 2023-07-07
PL3578201T3 (pl) 2023-09-11
PT3578201T (pt) 2023-05-10
ES2943932T3 (es) 2023-06-16
EP3578201B1 (en) 2023-04-19
US11617781B2 (en) 2023-04-04
US10874715B2 (en) 2020-12-29
DK3578201T3 (da) 2023-05-08
US10463715B2 (en) 2019-11-05
US20190117736A1 (en) 2019-04-25
AU2013282353B2 (en) 2018-10-25
SI3578201T1 (sl) 2023-06-30
EP2866834A4 (en) 2015-12-09
AU2019200525A1 (en) 2019-02-14
AU2019200525B2 (en) 2021-01-21
FI3578201T3 (fi) 2023-05-05
CA2877968A1 (en) 2014-01-03
EP2866834B1 (en) 2019-05-22
RS64172B1 (sr) 2023-05-31
LT3578201T (lt) 2023-05-25
EP4279579A3 (en) 2024-02-21
EP3578201A1 (en) 2019-12-11
EP2866834A1 (en) 2015-05-06
AU2013282353A1 (en) 2015-02-12
EP4279579A2 (en) 2023-11-22
AU2021202439B2 (en) 2024-09-05
US20170319659A1 (en) 2017-11-09
US20200138908A1 (en) 2020-05-07
US20230321191A1 (en) 2023-10-12
US20150190471A1 (en) 2015-07-09
HUE061931T2 (hu) 2023-09-28
WO2014005072A1 (en) 2014-01-03
AU2021202439A1 (en) 2021-05-13
SG10201610915XA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
SG10201610915XA (en) Methods and compositions for natural killer cells
HK1211620A1 (en) Natural killer cells and uses thereof
HK1208631A1 (en) Compositions and methods for immunotherapy
SG10201705024PA (en) Methods and compositions for separating or enriching cells
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL230237B (en) Fat Cell Compounds and Methods
EP2680837A4 (en) COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE
GB201200458D0 (en) Methods of preparing cells and compositions
IL227529A0 (en) Compounds and methods of cell transplantation
HK1205185A1 (en) Methods and composition related to brown adipose-like cells
EP2854530A4 (en) COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY
HK1206970A1 (en) Antigenic compositions and methods
IL229176A0 (en) Preparations of living cells and their uses
IL250307A0 (en) Pesticide preparations and methods
GB201315350D0 (en) Methods and compositions
ZA201308892B (en) Compositions and methods
GB201315347D0 (en) Methods and compositions
EP2766357A4 (en) MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR
IL239529A0 (en) Preparations and methods for creating improved and different cells and organisms
HK1231520A1 (zh) 改進的基質穩定性組合物和方法
HK1210436A1 (en) Novel cell compositions and methods
GB201116340D0 (en) Compositions and methods